Publications by authors named "Claire Ribet"
Background: Autoimmune and inflammatory diseases (AIDs) are a heterogeneous group of disorders with diverse etiopathogenic mechanisms. This study explores the potential utility of family history, together with present and past comorbidities, in identifying distinct etiopathogenic subgroups. This approach may facilitate more accurate diagnosis, prognosis and personalized therapy.
View Article and Find Full Text PDFArticle Synopsis
- A study examined low-dose interleukin-2 (IL-2) as a treatment for 13 different autoimmune diseases, focusing on its ability to activate regulatory T cells (Tregs) which are crucial in managing these conditions.
- 81 patients received IL-2 over a span of treatment, resulting in significant Treg expansion and activation, with clinical improvements noted in the majority of the diseases assessed, particularly in conditions like ankylosing spondylitis and systemic lupus erythematosus.
- The findings suggest that IL-2 is well-tolerated and effective at targeting Tregs, indicating its potential as a valuable addition to future therapeutic strategies for autoimmune diseases.
Objective: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential.
View Article and Find Full Text PDFIntroduction: Autoimmune and autoinflammatory diseases (AIDs) represent a socioeconomic burden as the second cause of chronic illness in Western countries. In this context, the TRANSIMMUNOM clinical protocol is designed to revisit the nosology of AIDs by combining basic, clinical and information sciences. Based on classical and systems biology analyses, it aims to uncover important phenotypes that cut across diagnostic groups so as to discover biomarkers and identify novel therapeutic targets.
View Article and Find Full Text PDF